Cytel Inc acquires the SDS Group
Av “It’s a perfect match - it’s fantastic for us and for Nordic life science,” says Anna Törner, founder of SDS Life Science, to Life Science Sweden.
Cytel Inc is headquartered in Waltham, Massachusetts and has approximately 2,000 employees.
“The company started with the development of statistical software and advanced analysis tools for the design of clinical studies but is now increasingly focusing on drug development and strategic consulting as a whole,” says Anna Törner.
The SDS Group consists of SDS Life Science and SDS MedteQ. The companies have approximately 60 employees and offer, among other things, consulting services in drug development, regulatory affairs, biostatistics, clinical project management and real-world evidence (RWE). In total, the two SDS companies had a turnover of SEK 78.6 million last year.
How does the acquisition affect SDS’s current operations?
“We are continuing the development of the SDS companies in the Nordics. The employees will continue their work, and the companies will look the same as today. The only difference is that Maria Lundberg, who is CEO, reports to the head office in the USA and will now become Managing Director for Sweden instead of CEO,” says Anna Törner.
“Cytel is a leader in clinical study design, RWE and clinical study design software, so for SDS, this means an opportunity to broaden our offer to our customers. It also means that we can continue to grow in Scandinavia. For Cytel, the acquisition strengthens them in our areas of strength, for example, drug development, regulatory affairs, clinical project management and medical technology.”
The management of the SDS companies remains the same as before with, among others, Maria Lundberg (CEO of SDS Life Science), Anna-Karin Alm (CEO of SDS MedteQ) and Anna Törner, founder.
“By fusing our like-minded knowledge pools, we are building critical new capabilities and enhancing our offering across every dimension important for efficiently developing novel therapies including pre-clinical, real world evidence, regulatory affairs, drug development, clinical project management, biostatics and medtech,” says Joshua Schultz, CEO of Cytel Inc, in a press release.
The acquisition is expected to close this quarter, subject to the fulfilment of the closing conditions.
Artikeln är en del av vårt tema om News in English.
